Was ist die Webseite?

Sclerosis MDPI

Startseite
Schweiz
Basel
Sclerosis MDPI

Sclerosis (ISSN 2813-3064) is an international, open access journal on all aspects of sclerosis and related diseases.

21/08/2026

🧬 Can a treatment for multiple sclerosis trigger a new inflammatory condition in the gut?

🔬 This case report describes a patient with multiple sclerosis who developed severe pancolitis and perianal disease following rituximab treatment, raising the possibility of anti-CD20-associated inflammatory bowel disease. The report reviews the literature and discusses a potential therapeutic approach following discontinuation of rituximab.

📄 Anti-CD20-Triggered Crohn’s-Like Disease with Severe Perianal Involvement in a Patient with Multiple Sclerosis: Case Report, Review of the Literature, and Potential Therapeutic Approach

✍️ Adrià Quesada-Simó, Francisco Giner, Lucas Barea-Moya, Alejandro Garrido-Marin, Alejandro Mínguez, Pilar Nos and Sara Gil-Perotín

🔗 https://brnw.ch/21x568p

20/08/2026

📱 What if your smartphone could become part of your MS care toolkit?

🧠 Fatigue is one of the most common and challenging symptoms of multiple sclerosis, yet its assessment often relies on what patients report.

🔎 This scoping review examined how smartphone applications are being used to assess and manage fatigue in MS. Across 16 studies, patients generally found these tools highly usable, while apps showed promising feasibility and reliability for distinguishing fatigue and supporting symptom management.

💡 As digital health continues to evolve, smartphone-based tools could offer patients more opportunities for monitoring and self-management at home.

📄 Role of Smartphone Applications in the Assessment and Management of Fatigue in Patients with Multiple Sclerosis: A Scoping Review

✍️ Annibale Antonioni, Andrea Baroni, Giada Milani, Irene Cordioli and Sofia Straudi

🔗 https://brnw.ch/21x54bA

19/08/2026

🇧🇷 How are multiple sclerosis treatments distributed and accessed across Brazil?

🔬 This comprehensive pharmacoepidemiological analysis maps therapeutic options for multiple sclerosis in Brazil, examining mechanisms of action, approval and free-distribution history, geographical patterns of use, and the potential impact of treatment availability on hospitalization and mortality.

📄 Mapping the Therapeutic Options for Multiple Sclerosis in Brazil: A Comprehensive Analysis

✍️ Chamberttan Souza Desidério, Yago Marcos Pessoa-Gonçalves, Rafael Obata Trevisan, Marlos Aureliano Dias-Sousa, Weslley Guimarães Bovi, Wellington Francisco Rodrigues, Marcos Vinicius da Silva, Virmondes Rodrigues Júnior and Carlo José Freire Oliveira

🔗 https://brnw.ch/21x52Fj

18/08/2026

🧠 What factors may increase the risk of cognitive impairment in people with multiple sclerosis?

🔬 This review examines the major risk factors associated with cognitive decline in MS, including neurodegeneration, smoking, vitamin D status, depression, and other clinical factors, while also exploring possible mechanisms and the impact of medication.

📄 Risk Factors for Cognitive Impairment in Multiple Sclerosis Patients

✍️ Thomas Gabriel Schreiner, Iustina Mihoc, Ecaterina Grigore and Oliver Daniel Schreiner

🔗 https://brnw.ch/21x50Dt

17/08/2026

🧠 Multiple sclerosis doesn’t only affect adults. What does the treatment landscape look like when MS begins before the age of 18?

🔎 Although pediatric-onset MS is relatively rare, young patients face unique challenges—and many therapies used in adults have limited pediatric clinical-trial evidence.

🚀 This review brings together current treatment options, emerging therapies, and the evolving evidence shaping the future of pediatric MS care.

📄 Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis

✍️ Artemis Mavridi, Maria Eleni Bompou, Aine Redmond, Paraschos Archontakis-Barakakis, George D. Vavougios, Dimos D. Mitsikostas and Theodoros Mavridis

🔗 https://brnw.ch/21x4YWb

14/08/2026

🧠 Could cognitive reserve influence how people with progressive multiple sclerosis respond to rehabilitation?

🔬 A secondary analysis of the RAGTIME trial found that people with higher cognitive reserve experienced significantly greater improvements in fatigue following gait rehabilitation.

🚶 While cognitive reserve did not significantly affect gait, balance, perceived disability, or depression, the findings suggest that it may play an important role in fatigue-related rehabilitation outcomes.

📖 The Cognitive Reserve May Influence Fatigue after Rehabilitation in Progressive Multiple Sclerosis: A Secondary Analysis of the RAGTIME Trial

✍️ Ambra Balzeri et al.

🔗 https://brnw.ch/21x4Vey

13/08/2026

🧠 What if understanding the immune cells behind MS could change how we treat the disease?

🔬 Multiple sclerosis is more than demyelination—it involves a complex interaction between adaptive and innate immune cells within the central nervous system. This review brings together histopathological and single-cell evidence to explore how these immune populations contribute to disease.

💊 These insights have already helped shape targeted treatments that can reduce relapses and new lesion formation and slow disease progression. But the search continues for therapies that can deliver greater benefits with fewer side effects.

📖 Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics

✍️ Manisha S. Patil, Linda Y. Lin, Felix Marsh-Wakefield, Elizaveta J. James, Mainthan Palendira, Simon Hawke and Georges E. Grau

🔗 https://brnw.ch/21x4TI0

🧬

12/08/2026

🧠 ALS is complex—but what happens when we connect the molecular pieces?

🧬 Researchers combined genetic, epigenetic, protein-interaction, and computational analyses to explore the mechanisms that may contribute to amyotrophic lateral sclerosis.

🔎 The study identified altered DNA methylation patterns and mutations affecting critical cellular processes, while computational screening pointed to Humulene and Buddledin C as promising SOD1-binding compounds for further investigation.

📖 Elucidating the Epigenetic and Protein Interaction Landscapes in Amyotrophic Lateral Sclerosis: An Integrated Bioinformatics Analysis

✍️ Katerina Kadena and Panagiotis Vlamos

🔗 https://brnw.ch/21x4RMc

07/08/2026

🧩 What if food could become part of the strategy for managing multiple sclerosis?

🥬 New research suggests that a modified Paleolithic diet may help improve functional abilities in people with MS, supporting better hand function and cognitive performance. While more research is needed, these findings highlight the growing connection between nutrition and neurological health.

📄 Diet-Induced Changes in Functional Disability among People with Multiple Sclerosis: A Secondary Pooled Analysis of Two Randomized Controlled Pilot Trials

✍️ Allison R. Groux, Elizabeth S. Walker, Farnoosh Shemirani, Jennifer E. Lee, Amanda K. Irish, Linda M. Rubenstein, Linda G. Snetselaar, Warren G. Darling, Terry L. Wahls, and Tyler J. Titcomb

🔗 https://brnw.ch/21x4Kr6

06/08/2026

🧠 Could biomarkers help identify multiple sclerosis progression before clinical symptoms make it obvious?

🔬 This systematic review evaluates biomarkers in serum, plasma, and cerebrospinal fluid that may distinguish relapsing-remitting MS (RRMS) from secondary progressive MS (SPMS). Six promising biomarkers emerged, offering new opportunities for earlier diagnosis and improved patient management.

📄 Biomarkers Differentiating RRMS and SPMS in Multiple Sclerosis—A Systematic Review

✍️ Camilla Toftegaard, Charlotte Marie Severinsen and Henrik Boye Jensen

🔗 https://brnw.ch/21x4ILB

Adresse

Basel

Webseite

https://www.mdpi.com/journal/sclerosis

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Sclerosis MDPI erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.